Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
85.2M
-
Shares change
-
+9.82M
-
Total reported value, excl. options
-
$3.38B
-
Value change
-
+$406M
-
Put/Call ratio
-
0.74
-
Number of buys
-
105
-
Number of sells
-
-69
-
Price
-
$39.71
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q1 2015
207 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q1 2015.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 85.2M shares
of 99.6M outstanding shares and own 85.51% of the company stock.
Largest 10 shareholders include FMR LLC (11.9M shares), PRICE T ROWE ASSOCIATES INC /MD/ (9.88M shares), ORBIMED ADVISORS LLC (5.83M shares), VANGUARD GROUP INC (3.94M shares), PERCEPTIVE ADVISORS LLC (3.74M shares), BlackRock Fund Advisors (3.25M shares), BB BIOTECH AG (3.2M shares), Visium Asset Management, LP (3.02M shares), PointState Capital LP (2.63M shares), and WESTFIELD CAPITAL MANAGEMENT CO LP (2.29M shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.